Press Releases Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
21.98 ^USD	-0.54%		-3.60%	-26.66%

16/04	Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	MT
11/04	Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02/04	BU
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team	27/03	BU
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?	05/03	PR
Rocket Pharmaceuticals: Q4 Earnings Snapshot	27/02	AQ
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	27/02	BU
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I	14/02	AQ
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)	13/02	BU
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference	03/01	BU
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors	12/12	BU
Rocket Pharmaceuticals: Q3 Earnings Snapshot	07/11	AQ
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress	07/11	BU
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene and Cell Therapy	20/23/20	AQ
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)	19/23/19	BU
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 for the Treatment of Severe Leukocyte Adhesion Deficiency-I	03/23/03	AQ
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)	02/23/02	BU
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference	27/23/27	BU
Rocket Pharmaceuticals, Moderna rise; American Airlines, Spirit Airlines fall, Wednesday, 9/13/2023	14/23/14	AQ
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock	13/23/13	BU
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock	13/23/13	BU
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease	13/23/13	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Press Releases

Filters